Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel beyond release criteria in relapsed/refractory B-cell non-Hodgkin lymphoma
ChiCTR2600130915Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of axicabtagene ciloleucel in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: best objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2600130915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130915.